FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Price Performance

Shares of FGEN opened at $0.33 on Monday. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93. The firm has a 50 day simple moving average of $0.35 and a 200-day simple moving average of $0.59. The stock has a market cap of $33.55 million, a price-to-earnings ratio of -0.27 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $46.33 million during the quarter, compared to analyst estimates of $34.00 million. During the same period last year, the firm earned ($0.52) earnings per share. On average, equities analysts expect that FibroGen will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of FibroGen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FGEN. Acadian Asset Management LLC boosted its position in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after acquiring an additional 860,854 shares during the last quarter. Doheny Asset Management CA purchased a new stake in shares of FibroGen during the 2nd quarter valued at $48,000. XTX Topco Ltd acquired a new stake in shares of FibroGen during the 2nd quarter worth $424,000. Sei Investments Co. increased its holdings in shares of FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares during the last quarter. Finally, Point72 DIFC Ltd boosted its holdings in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 45,990 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.